Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL5P22 (ribosomal protein L5 pseudogene 22) is a processed pseudogene found in the human genome. Unlike its parental gene RPL5, which encodes an essential ribosomal protein involved in protein synthesis and disease (e.g., Diamond-Blackfan anemia, various cancers), RPL5P22 does not produce a functional protein and is not associated with direct therapeutic or disease relevance. Pseudogenes such as RPL5P22 often accumulate mutations and do not participate in cellular functions. They are typically identified and annotated in genome databases for completeness but are not considered drug targets, nor do they serve as biomarkers or influence safety profiles in therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L5 pseudogene 22 (RPL5P22).